Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 236.58Cr 211.26Cr 195.17Cr 176.86Cr 330.89Cr 22TCr 336.37Cr 2.35TCr 929.82Cr 12TCr 887.85Cr 868.97Cr 37TCr P/E 2026 *
-177x
P/E 2027 * 36.2x
Enterprise Value 236.58Cr 211.26Cr 195.17Cr 176.86Cr 330.89Cr 22TCr 336.37Cr 2.35TCr 929.82Cr 12TCr 887.85Cr 868.97Cr 37TCr EV / Sales 2026 *
2.71x
EV / Sales 2027 * 1.74x
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week+7.44%
Current month-5.44%
1 month-5.98%
3 months-11.90%
6 months-18.21%
Current year-18.11%
1 week 37.76
Extreme 37.765
42.09
1 month 37.54
Extreme 37.54
44.93
Current year 37.54
Extreme 37.54
59.68
1 year 37.54
Extreme 37.54
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Exercice

Chief Technology Officer

4,097 0.0073%
12/08/26 Exercice

Chief Financial Officer

3,104 0.0055%
12/08/26 Exercice

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%+7.44%-22.96%+69.58% 236.58Cr
-2.54%+1.31%+54.27%+114.96% 1,13500Cr
-1.42%+3.23%+38.56%+74.44% 64TCr
+0.16%+0.08%+25.29%+95.23% 50TCr
-0.31%+3.09%+44.14%+64.80% 38TCr
-1.34%-0.47%+66.04%+41.00% 36TCr
-0.68%+2.65%+22.98%+50.39% 29TCr
-1.20%+3.04%+2.33%+22.86% 27TCr
-1.79%+1.57%+50.56%+59.08% 24TCr
-0.73%-0.10%+29.02%+99.67% 19TCr
Average -1.31%+2.69%+31.02%+69.20% 40.06TCr
Weighted average by Cap. -1.35%+2.66%+40.99%+79.75%

Financials

2026 *2027 *
Net sales 87Cr 78Cr 72Cr 65Cr 122.24Cr 8.3TCr 124.26Cr 867.63Cr 343.5Cr 4.35TCr 328Cr 321.02Cr 14TCr 135.86Cr 121.32Cr 112.08Cr 101.57Cr 190.02Cr 13TCr 193.16Cr 1.35TCr 533.96Cr 6.76TCr 509.86Cr 499.02Cr 21TCr
Net income -1.34Cr -1.19Cr -1.1Cr -1Cr -1.87Cr -127.03Cr -1.9Cr -13Cr -5.26Cr -67Cr -5.02Cr -4.92Cr -209.83Cr 6.54Cr 5.84Cr 5.4Cr 4.89Cr 9.15Cr 620.93Cr 9.3Cr 65Cr 26Cr 325.33Cr 25Cr 24Cr 1.03TCr
Net Debt - -
Projected Income Statement - Annual - Supernus Pharmaceuticals, Inc.
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
23/26/23 $40.70 -3.26% 11,59,336
22/26/22 $42.07 +2.09% 9,37,419
21/26/21 $41.21 -0.05% 10,06,298
20/26/20 $41.23 +3.49% 12,40,345
19/26/19 $39.84 +5.17% 15,09,140
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Supernus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
40.70USD
Average target price
60.50USD
Spread / Average Target
+48.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Supernus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SUPN Stock